Cel-sci Corporation · AMEX:CVM
Cel-sci — Investor Presentation (September 2026)
21 slides from Cel-sci's investor presentation, September 2026
Slide 1: Multikine: A First-In-Class Cancer Immunotherapy
Multikine “A First-In-Class Cancer Immunotherapy” Activating the immune system to fight cancer BEFORE the ravages of surgery, radiation and chemotherapy September 2026 NYSE American: CVM
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties. Please refer to our public filings for full disclosure. This presentation contains “forward-looking statements” standards; our expectations regarding federal, state by applicable la
Slide 3: CEL-SCI's Story in Short: Strong Phase 3 Head & Neck Cancer Data
CEL-SCI’s Story in Short: Strong Phase 3 Head & Neck Cancer Data • We have developed an immune based cancer drug designed to increase the “cure” rate of cancer patients. • This drug is called Multikine (many cytokines) and is not toxic. • Multikine is designed to activate the immune system to fight
Slide 4: Multikine Treatment Sequence
Multikine Treatment Sequence • Multikine is given before the standard therapies, right after diagnosis. It enhances the immune system when it is strongest. • The completed 928-patient Phase 3 study showed survival benefit for the group of patients who were treated with surgery and radiotherapy, but
Slide 5: U.S. Confirmatory Registration Study Ready for Patient Enrollment
U.S. Confirmatory Registration Study Ready for Patient Enrollment • One single study of 212 patients is needed for registration. We select the patients who showed the best survival in the prior study: same population, but patients must be N0 and PD-L1 low/zero. • This study is a repeat, enrolling on
Slide 6: Why Do We Think This Study Has a Very High Chance of Success?
Why do we Think that this Study has a very high Chance of Success? Consistent Signals Across All Efficacy Measures to Validate Overall Survival U.S. Confirmatory Registration Study will only enroll the target population that had these results in the Phase 3 study • 73% overall survival (OS) with Mul
Slide 7: Multikine Improved Survival in the Completed Phase 3 Study
Multikine Improved Survival in the Completed Phase 3 Study Target Population (No lymph node involvement & PD-L1 low) for Confirmatory Study • No safety signals or toxicities vs standard of care • 5-year survival: 73% (Multikine) vs. 45% (Control) Multikine • Statistically significant (log rank p = 0
Slide 8: Multikine Survival Data Superior to Keytruda in Locally Advanced Resectable HNSCC
Multikine Survival Data Superior to Keytruda in Locally Advanced Resectable HNSCC CEL-SCI to confirm Multikine’s prior survival results in its 212-patient Confirmatory Registration Study Merck: Keytruda (Pembrolizumab) CEL-SCI: Multikine Newly diagnosed, resectable locally advanced Newly diagnosed,
Slide 9: Multikine Survival Data Compare Favorably with a $45 Billion Oncology Asset
Multikine Survival Data Compare Highly Favorably with One of Oncology’s Most Highly Valued Investigational Assets at $45 Billion Revolution Medicines (Nasdaq: RVMD) demonstrates how the market can value a late-stage oncology asset that delivers a major survival benefit. If CEL-SCI confirms Multikine
Slide 10: The Need for Innovation in Head & Neck Cancer
The Need for Innovation in Head & Neck Cancer Head & neck cancer: • 6th most common cancer • ~900,000 newly diagnosed patients per year • Global head and neck cancer market: $2.58 billion in 2024, projected to reach $7.68 billion 1 by 2034 • Severe unmet medical need • The targeted patient populatio
Slide 11: Our Registration Study Design
Our Registration Study Design Stage 1: Treatment Period Stage 2: Follow-up period Treatment Arm Multikine treatment first then standard of care n=106 Assess overall survival as the primary Randomized 1:1 between the efficacy endpoint, and then treatment arm and the control arm histopathology biomark
Slide 12: Market Opportunity: Targeting a Significant Patient Population
Market Opportunity: Targeting a Significant Patient Population Multikine is poised to address a substantial segment of the head and neck cancer market, particularly patients with low or zero PD-L1 expression who are not served by the current blockbuster immunotherapy Keytruda. This represents a sign
Slide 13: How Multikine Works
How Multikine Works N0 means intact local immune architecture can • Multikine is a mix of mount an effective immune natural cytokines that attack on the tumor prime immune cells • Administered near tumor and draining lymph nodes before surgery • Helps immune cells overcome tumor defenses • Higher ef
Slide 14: Tumor Cell Death Without And With Multikine
Tumor Cell Death Without And With Multikine Without Multikine With Multikine How the Tumor Defense How Multikine May Circumvent T cells T cells Mechanisms Can The Tumor Defense Mechanisms! Circumvent An Anti-tumor LYMPH Immune Response LYMPH NODE NODE T DC cells T Kill Tumor DC DC cells (GzmB, PFN;
Slide 15: Some Patients Have Complete Tumor Elimination in Just 3 Weeks
Some Patients Have Complete Tumor Elimination in Just 3 Weeks, Confirmed by Pathology Oral Squamous Cell Carcinoma (Locally Advanced Primary H&N Cancer) Histological appearance of necrosis in Oral Squamous Cell Carcinoma (OSCC) [HE staining]: Non-Multikine treated Multikine treated Lack of necrosis
Slide 16: Increased Pre-Surgical Tumor Responses Predict for Survival Across All Patients
Increased Pre-Surgical Tumor Responses Predict for Survival Across All Patients (n=928) in the Phase 3 Trial 16
Slide 17: Even Higher PSR/PSD Rates in the Target Population (n=114)
As Expected, Even Higher PSR/PSD Rates in the Target Population (n=114) 17
Slide 18: Amarox – Strategic Partner in Saudi Arabia
Amarox – Strategic Partner in Saudi Arabia In May 2026, CEL-SCI signed a strategic partnership, distribution, and revenue sharing agreement with Amarox for regulatory affairs, marketing and potential commercialization of Multikine • 50%/50% revenue sharing agreement for Multikine sales in Saudi Arab
Slide 19: Manufacturing Readiness: Prepared for Global Supply
Manufacturing Readiness: Prepared for Global Supply An investment of over $200 million has been made into Multikine manufacturing, ensuring that Multikine can be produced at scale to meet anticipated global demand upon potential approval. +$200 M Decades Barrier to competition – Process of manufactu
Slide 20: Investment Highlights
Investment Highlights • Strong Phase 3 Survival Benefit: Multikine demonstrated a 73% five-year survival rate in the target head & neck cancer population versus 45% in the control group, with a hazard ratio of 0.34 (95% CIs [0.19, 0.66]). Patients also showed meaningful tumor shrinkage, progression
Slide 21: Thank you!
Thank you! NYSE American: CVM